Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Teva must have the whole enoxaparin market. Lot's of good it's doing for them.



Amphastar Results:

For the three months ended June 30, 2017, net revenues of enoxaparin were $8.3 million, representing a decrease of 52% compared to $17.3 million for the three months ended June 30, 2016. Of the decrease, $7.1 million was due to lower unit volumes, while the remainder was due to lower pricing.